Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
Grundium White Paper: How Compact, On-Demand Whole-Slide Imaging (WSI) Delivers High-Quality & Timely Diagnoses
February 2026—Prepared with expert insight from Anil Parwani, MD, PhD; Scott Hammond; and Melinda Schumacher, MD, Grundium’s white paper describes, from a pathologist’s perspective, how compact WSI systems can shorten consult turnaround times and reduce variability, improve access to subspecialty review without adding travel or courier burden, enhance community pathologists’ professional satisfaction and confidence, support scalable, secure, and validated workflows and lay the foundation for AI and advanced analytics as digital adoption grows. Download the white paper here.
Improved Molecular Results for BOMs with Automated Decalcification
LeanDECAL automates fixation and decalcification using temperature control and EDTA chemistry. Validated protocols preserve morphology, IHC, RNA, and DNA. Learn More
Biocartis and Mayo Clinic enter into research collaboration
Jan. 13, 2026—Biocartis has entered into a research collaboration with Mayo Clinic to develop a rapid sample-to-answer test aiming to decrease the time to treatment for breast cancer patients.
AMA approves PLA code for RenaDx kidney genetics panel
Jan. 6, 2026—The American Medical Association has approved a new CPT proprietary laboratory analyses code for Personalized Medicine Care Diagnostics’ RenaDx, a comprehensive kidney genetics panel. The PLA code, 0628U, will become effective April 1.
Automated and integrated genomic profiling of hematologic malignancies
Thursday, March 5, 2026
11:00 AM–12:00 PM ET
Learn how EuroClonality-NDC and Myeloid-NDC NGS Workflows are utilized in advancing the future of diagnostics, prognostics, and targeted therapies and how these revolutionary assays provide comprehensive genomic data that reveals mutations, structural variations, and clonal evolution patterns with remarkable resolution, enabling clinical researchers to delve deeper into the genomic landscape of hematological malignancies.
Webinar presenters David Gonzalez, PhD, FRCPath, CEO, Univ8 Genomics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
Foundation of HER2 Gastric Cancer ASCO/CAP Guidelines—Overview of the Differences Between ASCO-CAP Breast and Gastric Cancer Scoring
Wednesday, January 28, 2026
12:00 PM–1:30 PM ET
Understand the clinical relevance of HER2 as a biomarker and its importance in cancers beyond breast and gastric. Explore the nuances of HER2 IHC scoring for breast and gastric cancers. Hear expert insights on current gastric ASCO/CAP guidelines for scoring.
Webinar presenters Josef Rüschoff, MD, PhD.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
Unlocking Fertility Insights: The Power of AMH in Reproductive Health-September 24, 2025
Webinar presenters Wendy Vitek, MD, Board-certified Reproductive Endocrinologist, Boston IVF’s Syracuse, NY Fertility Center, and Shirley Li, MD, PhD, Associate Professor-Clinical, Department of Pathology; Director of Clinical Pathology Services and Co-Director of the Clinical Chemistry & Toxicology Laboratory, The Ohio State University, explore Anti-Müllerian Hormone (AMH) from both analytical and clinical perspectives.
Experience Epredia Pathology Solutions
Comprehensive solutions for every step in your workflow. Delivery Innovation to pathology labs worldwide. Learn More
Diasorin gets clearance, waiver for fourplex panel
Dec. 29, 2025—Diasorin has received FDA 510(k) clearance and CLIA waiver for its first assay, the Flu A/B, RSV and COVID-19 panel, to be used on the Liaison Nes point-of-care molecular diagnostic platform.